Patents by Inventor Karoly Nikolich

Karoly Nikolich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11382907
    Abstract: Methods of improving neurodegenerative disease with CCR3 modulating agents are provided. The methods include administering a therapeutically effective amount of the CCR3 modulating agent to the subject, with a concomitant improvement in cognition, motor, or other neurodegenerative-affected function. Cognitive and motor diseases upon which the methods of the invention can improve cognition include Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, glaucoma, myotonic dystrophy, vascular dementia, progressive supranuclear palsy.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: July 12, 2022
    Assignee: Alkahest, Inc.
    Inventors: Steven P. Braithwaite, S. Sakura Minami, Karoly Nikolich
  • Publication number: 20220152161
    Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.
    Type: Application
    Filed: January 24, 2022
    Publication date: May 19, 2022
    Inventors: David Bell, Ian Gallager, Steven P. Braithwaite, S. Sakura Minami, Vu Dang, Joe McCracken, Karoly Nikolich
  • Publication number: 20210386981
    Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.
    Type: Application
    Filed: June 22, 2021
    Publication date: December 16, 2021
    Applicant: NEUROFLUIDICS, INC.
    Inventors: SHIVANAND LAD, WILLIAM C. MOBLEY, KAROLY NIKOLICH, THOMAS SAUL
  • Publication number: 20210386982
    Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.
    Type: Application
    Filed: June 22, 2021
    Publication date: December 16, 2021
    Applicant: NEUROFLUIDICS, INC.
    Inventors: SHIVANAND LAD, WILLIAM C. MOBLEY, KAROLY NIKOLICH, THOMAS SAUL
  • Patent number: 11065425
    Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: July 20, 2021
    Assignee: Neurofluidics, Inc.
    Inventors: Shivanand Lad, William C. Mobley, Karoly Nikolich, Thomas Saul
  • Patent number: 11040179
    Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: June 22, 2021
    Assignee: Neurofluidics, Inc.
    Inventors: Shivanand Lad, William C. Mobley, Karoly Nikolich, Thomas Saul
  • Publication number: 20210106577
    Abstract: Methods of improving visual endpoints related to retina-associated disease with CCR3 modulating agents are provided. An example of such an endpoint is visual acuity. Retina-associated diseases upon which visual acuity and other visual endpoints may be improved include retinopathy of prematurity, age-related macular degeneration, central retinal vein occlusion, and diabetic retinopathy.
    Type: Application
    Filed: April 4, 2018
    Publication date: April 15, 2021
    Inventors: Laura Coradini, Sam Jackson, Karoly Nikolich
  • Publication number: 20200054622
    Abstract: Methods of improving neurodegenerative disease with CCR3 modulating agents are provided. The methods include administering a therapeutically effective amount of the CCR3 modulating agent to the subject, with a concomitant improvement in cognition, motor, or other neurodegenerative-affected function. Cognitive and motor diseases upon which the methods of the invention can improve cognition include Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, glaucoma, myotonic dystrophy, vascular dementia, progressive supranuclear palsy.
    Type: Application
    Filed: September 25, 2019
    Publication date: February 20, 2020
    Inventors: Steven P. Braithwaite, S. Sakura Minami, Karoly Nikolich, Sanket V. Rege, Arnaud E.J. Teichert
  • Publication number: 20200046954
    Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.
    Type: Application
    Filed: August 22, 2019
    Publication date: February 13, 2020
    Applicant: NEUROFLUIDICS, INC.
    Inventors: SHIVANAND LAD, WILLIAM C. MOBLEY, KAROLY NIKOLICH, THOMAS SAUL
  • Patent number: 10525107
    Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: January 7, 2020
    Assignee: Alkahest, Inc.
    Inventors: David Bell, Ian Gallager, Steven P. Braithwaite, S. Sakura Minami, Vu Dang, Joe McCracken, Karoly Nikolich
  • Patent number: 10487148
    Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include reducing the 2-microglobulin (B2M) level in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: November 26, 2019
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, U.S. GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, ALKAHEST, INC.
    Inventors: Anton Wyss-Coray, Saul A. Villeda, Karoly Nikolich
  • Publication number: 20190321449
    Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.
    Type: Application
    Filed: June 28, 2019
    Publication date: October 24, 2019
    Inventors: David Bell, Ian Gallager, Steven P. Braithwaite, S. Sakura Minami, Vu Dang, Joe McCracken, Karoly Nikolich
  • Patent number: 10398884
    Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: September 3, 2019
    Assignee: NEUROFLUIDICS, INC.
    Inventors: Shivanand Lad, William C. Mobley, Karoly Nikolich, Thomas Saul
  • Publication number: 20190106495
    Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include reducing the ?2-microglobulin (B2M) level in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.
    Type: Application
    Filed: October 23, 2018
    Publication date: April 11, 2019
    Inventors: Anton Wyss-Coray, Saul A. Villeda, Karoly Nikolich
  • Publication number: 20190105314
    Abstract: Methods of improving neurodegenerative disease with CCR3 modulating agents are provided. The methods include administering a therapeutically effective amount of the CCR3 modulating agent to the subject, with a concomitant improvement in cognition, motor, or other neurodegenerative-affected function. Cognitive and motor diseases upon which the methods of the invention can improve cognition include Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, glaucoma, myotonic dystrophy, vascular dementia, progressive supranuclear palsy.
    Type: Application
    Filed: April 4, 2018
    Publication date: April 11, 2019
    Inventors: Steven P. Braithwaite, S. Sakura Minami, Karoly Nikolich
  • Publication number: 20180298102
    Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include reducing the 2-microglobulin (B2M) level in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.
    Type: Application
    Filed: May 17, 2016
    Publication date: October 18, 2018
    Inventors: Anton Wyss-Coray, Saul A. Villeda, Karoly Nikolich
  • Publication number: 20180110839
    Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.
    Type: Application
    Filed: April 27, 2017
    Publication date: April 26, 2018
    Inventors: David Bell, Ian Gallager, Steven P. Braithwaite, S. Sakura Minami, Vu Dang, Joe McCracken, Karoly Nikolich
  • Patent number: 9895518
    Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a multilumen flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: February 20, 2018
    Assignee: NEUROFLUIDICS, INC.
    Inventors: Shivanand Lad, William C. Mobley, Karoly Nikolich, Thomas Saul
  • Publication number: 20170203084
    Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.
    Type: Application
    Filed: January 19, 2017
    Publication date: July 20, 2017
    Inventors: Shivanand Lad, William C. Mobley, Karoly Nikolich, Thomas Saul
  • Publication number: 20140066830
    Abstract: The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a multilumen flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 6, 2014
    Applicant: Neurofluidics, Inc.
    Inventors: Shivanand Lad, William C. Mobley, Karoly Nikolich, Thomas Saul